Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?
Prolab
GNC to carry more than 20 Natrol sports nutrition products for first time, manufacturer announces May 22. Prolab gondola display will be used at retail chain's 4,500 stores under multi-year deal, which Natrol expects to be first stage of long-term relationship with GNC. Ads will note availability of Prolab supplements at GNC outlets and brand's logo will be featured in GNC's NASCAR sponsorship promotions. Natrol, which hopes to attract more casual exercisers in addition to dedicated athletes, says new products, such as EcdyVone anabolic accelerator slated for summer debut, will be highlighted. Products will accompany GNC store brands and offerings from other marketers, such as Twinlab and Weider - both of which have reported declining sales to GNC stores (1"The Tan Sheet" April 9, p. 7 and 2Jan. 15, p. 12)
More from Archive
• By
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
• By
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
• By
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
• By
In its latest attempt to curtail generic versions of Hetlioz, Vanda Pharmaceuticals asked FDA Commissioner Martin Makary to reverse a previous agency decision upholding two ANDA approvals, claiming an “unacceptable culture of bias toward approving generic drugs” at the agency.
• By
Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.
• By
Health Canada has approved four new drugs and 12 label variations so far this year via Project Orbis, a combined figure that already exceeds the annual approval figures for the two previous years. The agency explains the factors that impact annual approvals and highlights the pathway’s benefits.